Page 245

TABLE F-2 Pharmaceutical Companies: Current (1999) Prospects for Development of New Antituberculosis Drugs and Vaccines New Antimicrobials Available in: Company 2 Years 5 Years 8 Years Vaccines Abbott Laboratories 0 0 0 0 American Home Products (Lederle/Wyeth-Ayerst) 0 0 0 0 Astro-Zeneca Pharmaceuticals 0 0 0 0 Bristol-Myers Squibb 0 0 0 0 Dupont Pharmaceuticals 0 ?oxazolidinones ?oxazolidinones 0 Eli Lilly and Company 0 0 0 0 Glaxo-Wellcome 0 0 ? Working on vaccines DNA Whole attenuated live organism Therapeutic vaccine Hoechst Marion Roussel 0 0 0 0 Rifapentine approved by FDA in 1998 Janssen Pharmaceuticals 0 0 0 0 Merck and Company 0 0 0 Very exploratory; have rights to a DNA vaccine in the public domain. Would also be interested in a subunit vaccine Page 245 Front Matter (R1-R18) Executive Summary (1-12) 1 Fundamentals of Tuberculosis and Tuberculosis Control (13-22) 2 The Current Situation and How We Got Here (23-50) 3 Tuberculosis Elimination and the Changing Role of Tuberculosis Control Programs (51-85) 4 Advancing Toward Elimination (86-121) 5 Developing the Tools for Tuberculosis Elimination (122-148) 6 The U.S. Role in Global Tuberculosis Control (149-158) 7 Mobilizing for Elimination (159-168) Appendix A Statement of Task (169-172) Appendix B Public Session Agendas (173-181) Appendix C Site Visit Summaries (182-204) Appendix D Role of Public Health Laboratories in the Control of Tuberculosis (205-233) Appendix E Estimating the Number of Tuberculosis Cases That Can Be Prevented by a Program of Screening and Preventive Therapy of Newly Arrived Immigrants to the United States from Countries with a High Rate of Tuberculosis a (234-243) Appendix F Approval Dates for Existing and Prospects for Development of New Antituberculosis Drugs and Vaccines (244-249) Appendix G Committee Biographies (250-256) Index (257-269)